Cortical Resections in Drug Resistant Epilepsy

Status Not yet recruiting

Clinical Trial Summary

The aim of the study is to evaluate safety and efficacy of epilepsy surgery in the form of cortical resections in patients with refractory epilepsy and to review outcomes of resection procedures in focal epilepsy.

Clinical Trial Description

Nearly one-third of epilepsy patients are refractory/resistant to medical treatment . Refractory or drug-resistant epilepsy is defined as resistance to treatment with two appropriately chosen and tolerated antiepileptic drugs (AED) . Nevertheless, epilepsy surgery is an effective alternative treatment for some patients as it suggests seizure freedom . During the past 3 decades, surgery has found more acceptance as an option for drug-resistant epilepsy . Developments made in surgical techniques (cortical resections) have significantly increased the effectiveness and safety of these techniques; as such techniques have been demonstrated to improve seizure control/freedom outcomes and enhanced quality of life in patients . Neuro imaging developments with the introduction of positron emission tomography (PET), magnetic resonance imaging (MRI), functional MRI, single-photon emission computed tomography (SPECT), and magneto encephalography, electroencephalography and neuronavigation have facilitated the presurgical evaluation of patients, thus providing the lesion-directed surgeries more possible , also reducing the number and severity of complications . Complications of epilepsy surgery including failure to stop seizures and neuropsychological, psychosocial, or psychiatric impairment are still difficult to define, and there is no universal consensus in this regard .

This technique characterized by :

• Once the epilepsy focus is located by using interpretation and collection of data from functional MRI, EEG long term video and clinical findings, the specific surgery involved in treatment is decided on. The type of surgery depends on the location of the seizure focal point. Surgeries for epilepsy treatment include, but are not limited to, the following types: temporal lobe resection, ground temporal and extra temporal resection, parietal resection, occipital resection, frontal resection, extra temporal resection. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04553354
Study type	Observational
Source	Assiut University
Contact	mahmoud mostafa ammar, assistant lecturer
Phone	+201026998340
Email	dr.mahmoud.ammar90@gmail.com
Status	Not yet recruiting
Phase
Start date	September 10, 2020
Completion date	November 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04378075` - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy	Phase 2/Phase 3
Recruiting	`NCT05928598` - Goals for Epilepsy Clinic Visits Trial	N/A
Recruiting	`NCT05539287` - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy	Phase 2
Not yet recruiting	`NCT04601974` - Lentiviral Gene Therapy for Epilepsy	Phase 1/Phase 2
Completed	`NCT02982824` - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy	N/A
Recruiting	`NCT05485558` - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy	Phase 2
Recruiting	`NCT04999046` - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy	N/A
Recruiting	`NCT04714996` - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy	Phase 2
Recruiting	`NCT04839601` - RNS System RESPONSE Study	N/A
Recruiting	`NCT06059157` - Epileptogenic Network Visualisation With Advanced MRI	N/A
Recruiting	`NCT05947656` - Evaluation of the NaviFUS System in Drug Resistant Epilepsy	N/A
Recruiting	`NCT05393518` - Electroclinical Correlation of Anxiety	N/A
Not yet recruiting	`NCT05555537` - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed	`NCT03419000` - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY	N/A
Enrolling by invitation	`NCT06341075` - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy	N/A
Not yet recruiting	`NCT05527093` - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy	N/A
Recruiting	`NCT05697614` - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children	Phase 4
Recruiting	`NCT06309251` - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Not yet recruiting	`NCT06340802` - A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl	N/A
Completed	`NCT03860298` - Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.